Tamura K, Okayama A, Koga K, Sagawa K, Seita M, Tachibana N, Tsuda K
Jpn J Clin Oncol. 1983;13 Suppl 2:313-24.
Adult T-cell leukemia (ATL) is an extremely difficult disease to treat. The median survival of patients with this disease has been reported to be only about 3 mo even with intensive treatment. We have treated five ATL patients (four males and one female, 42 to 72 yr of age) with total body irradiation (TBI). One patient who received 150 rad of TBI achieved complete remission and has been well without treatment for over a year. One hundred and thirty rad of TBI was administered to another patient, resulting in control of the leukocyte count at around 10,000/microliter and survival for 6 mo. Three patients received 100 rad of TBI. Only one of these patients has lived with leukemic cells for over a year without treatment. The other two patients relapsed rapidly and despite various kinds of treatment, such as a second course of TBI, extracorporeal irradiation of the blood, cytapheresis and combination chemotherapy consisting of pepleomycin, vincristine and a high dose of prednisolone, expired from pneumonia in 3 and 4 mo respectively. In all except the last two patients, thrombocytopenia and anemia developed and lasted for 2.5 wk to 3 mo and granulocytopenia occurred only in the patient who received 150 rad of TBI. Slight nausea and loss of appetite were noticed in one patient. It seems that 100 to 150 rad of TBI is effective against ATL, with acceptable side effects.
成人T细胞白血病(ATL)是一种极难治疗的疾病。据报道,即使经过强化治疗,该疾病患者的中位生存期也仅约为3个月。我们对5例ATL患者(4例男性,1例女性,年龄42至72岁)进行了全身照射(TBI)治疗。1例接受150拉德TBI照射的患者实现了完全缓解,且未经治疗已健康存活超过1年。另1例患者接受了130拉德的TBI照射,白细胞计数控制在约10,000/微升左右,存活了6个月。3例患者接受了100拉德的TBI照射。这些患者中只有1例在未接受治疗的情况下,白血病细胞携带状态存活超过1年。另外2例患者迅速复发,尽管接受了各种治疗,如第二轮TBI照射、血液体外照射、血细胞分离术以及由培普利霉素、长春新碱和高剂量泼尼松龙组成的联合化疗,但分别在3个月和4个月时因肺炎死亡。除最后2例患者外,所有患者均出现了血小板减少症和贫血,持续时间为2.5周 至3个月,粒细胞减少仅发生在接受150拉德TBI照射的患者中。1例患者出现了轻微恶心和食欲不振的症状。看来100至150拉德的TBI照射对ATL有效,且副作用可接受。